Thursday, December 29, 2016
Thursday, December 22, 2016
Thursday, December 15, 2016
Friday, December 9, 2016
Friday, December 2, 2016
Thursday, November 24, 2016
Monday, November 21, 2016
Thursday, November 10, 2016
Call For Paper
10:35 PM
No comments
Bentham Science Publishers would like to invite you to submit your research paper for publishing in the Journal of
Thursday, November 3, 2016
Highlighted Article: Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
4:33 AM
No comments
Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Author(s):
Christos Kontogiorgis, Ioannis Valikeserlis, Dimitra Hadjipavlou-Litina, Evangelia Nena and Theodoros C. Constantinidis Pages 502 - 513 ( 12 )
Abstract:
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used, having numerous indications. However, despite their therapeutic role, they are associated with serious cardiovascular (CV) adverse events.
Objectives-Methods: This review comprising recent observational studies and metaanalyses over the past few years aims at updating the assessment of CV adverse events, namely stroke, myocardial infarction (MI), CV death, atrial fibrillation (AF), serious bleeding and heart failure related to the use of 4 of the most widely prescribed NSAIDs: ibuprofen, naproxen, diclofenac and mefenamic acid.
Results: The best safety profile related to MI was found for naproxen, while the worst safety profile, with excessively increased risk for stroke, MI and major bleeding, was for diclofenac. Naproxen showed higher risk for major bleeding than ibuprofen and the risk for stroke was slightly higher than ibuprofen. Regarding heart failure, ibuprofen presented the highest risk while the highest risk for AF was attributed to the current use of diclofenac. There are few data related to mefenamic acid, which showed a strong association with increased risk for stroke and a moderately increased risk for MI.
Conclusion: Further research is needed in order to devise new guidelines for safer use of NSAIDs.
Keywords:
Cardiovascular, safety, adverse events, diclofenac, ibuprofen, naproxen, mefenamic acid, stroke, myocardial infarction.
Affiliation:
Laboratory of Hygiene and Environmental Protection, Medical School, Democritus University of Thrace, Campus (Dragana) Building 5, GR-68100 Alexandroupolis, Greece.
For More Information Please Visit Our Website Current Vascular Pharmacology
Thursday, October 27, 2016
Most Cited Article: Sulodexide Down-Regulates the Release of Cytokines, Chemokines, and Leukocyte Colony Stimulating Factors from Human Macrophages: Role of Glycosaminoglycans in Inflammatory Pathways of Chronic Venous Disease
3:11 AM
No comments
Sulodexide
Down-Regulates the Release of Cytokines, Chemokines, and Leukocyte Colony
Stimulating Factors from Human Macrophages: Role of Glycosaminoglycans in
Inflammatory Pathways of Chronic Venous Disease
Author(s):
Ferdinando Mannello, Daniela Ligi, Matteo
Canale and Joseph D. Raffetto Pages 173 - 185 ( 13 )
Abstract:
Chronic venous disease (CVeD) is a
debilitating condition that affects millions of individuals worldwide. The condition
can result in varicose veins, or advance to severe skin changes and venous
ulceration. The fundamental basis for CVeD is inflammation within the venous
circulation and that it is subjected to increased hydrostatic pressure
resulting in increased ambulatory venous pressure. The inflammation involves
leukocytes, in particular macrophages and monocytes, inflammatory modulators
and chemokines, cytokine expression, growth factors, metalloproteinase (MMP)
activity, and many regulatory pathways that perpetuate inflammation.
Sulodexide (SDX) is a glycosaminoglycan with
pro-fibrinolytic and anti-thrombotic properties. We have previously
demonstrated that SDX inhibits the secretion of pro-zymogen MMP-9 from human
leukocytes without displacing high molecular complexes of MMP-9. The
anti-inflammatory properties of SDX on activated leukocytes have not been well
established. We hypothesized that SDX will reduce the secretion of inflammatory
mediators from lipopolysaccharide (LPS)-stimulated macrophages. Therefore, we
evaluated the effects of SDX on LPS-stimulated macrophage secretion of various
inflammatory and anti-inflammatory cytokines, chemokines, and colony
stimulating factors. We used microplatebased multiplex immunoassays.
LPS-stimulated macrophages in vitro caused a substantial increase of
interleukins, tumor necrosis factor, interferon, chemokines and colony
stimulating factors. The addition of SDX caused both a dose-dependent and
dose-independent decrease in nearly all of the inflammatory cytokines, chemokines
and colony stimulating factors. These findings suggest that SDX has a
significant effect on the release of inflammatory mediators from macrophages,
and may be useful in the treatment of early and advanced CVeD.
Keywords:
Chronic venous disease, inflammation,
glycosaminoglycan, pro-inflammatory cytokines, chemokines, sulodexide, U-937
macrophage-like cell line.
Affiliation:
Department of Biomolecular Sciences, Section
of Clinical Biochemistry and Cell Biology, University “Carlo Bo”, Via O.
Ubaldini 7, Urbino (PU), Italy.
For More Information Please Visit Our Website Current Vascular Pharmacology
Thursday, October 20, 2016
Thursday, October 13, 2016
Current Vascular Pharmacology, Volume 14 - Number 5
4:41 AM
No comments
Contents
Current Vascular Pharmacology, Volume 14 - Number 5
Meet Our Editorial Board Member:
, 14(5): 405Gaetano Santulli.
DOI: 10.2174/138955751617161006172636
Eprints Rights and Permissions
Editorial (Thematic Issue: Sex, Environment, Physical Activity, Diet, and Obesity in Cardiovascular Disease Risk)
, 14(5): 406 - 408Debabrata Mukherjee and Thomas F Whayne.
DOI: 10.2174/138955751617161006172905
Order Eprints Rights and Permissions
Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
, 14(5): 415 - 425Sarmad Said, Debabrata Mukherjee and Thomas F Whayne.
DOI: 10.2174/1570161114666160722121615
Use of Chronic Disease Registries to Optimize Cardiovascular Health
, 14(5): 426 - 431Sucheta Gosavi and Aparna Bhagavat.
DOI: 10.2174/1570161114666160722114413
Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
, 14(5): 432 - 441Niki Katsiki, Vasilios G. Athyros and Dimitri P Mikhailidis.
DOI: 10.2174/1570161114666160722112738
The Mediterranean and other Dietary Patterns in Secondary Cardiovascular Disease Prevention: A Review
, 14(5): 442 - 451Demosthenes B. Panagiotakos, Venetia Notara, Matina Kouvari and Christos Pitsavos.
DOI: 10.2174/1570161114999160719104731
Cardiovascular Risk Factors: Does Sex Matter?
, 14(5): 452 - 457Gretchen L Wells.
DOI: 10.2174/1570161114666160722113116
Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
, 14(5): 458 - 465Thomas F. Whayne and Debabrata Mukherjee.
DOI: 10.2174/1570161114999160719104936
Editorial: Time for Earlier and More Intensive Preventive Therapy
, 14(5): 466 - 468Kosmas I. Paraskevas and J David Spence.
DOI: 10.2174/1570161114666160909161319
Order Reprints Order Eprints Rights and Permissions
Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
, 14(5): 469 - 473Vasilios G. Athyros, Niki Katsiki and Nikolaos Tentolouris.
DOI: 10.2174/1570161114666160909161537
Order Reprints Order Eprints Rights and Permissions
Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
, 14(5): 474 - 480Vasileios G. Chantzichristos, Aris P. Agouridis, Elisavet Moutzouri, Konstantinos Stellos, Moses S. Elisaf and Alexandros D Tselepis.
DOI: 10.2174/1570161114666160404125341
Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure
, 14(5): 481 - 486Mansour Sallam, Tariq Al-Saadi, Latifa Alshekaili and Ibrahim Al-Zakwani.
DOI: 10.2174/1570161114666160505143003
Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation
, 14(5): 487 - 491Ioanna Xanthopoulou, Chrysoula Vogiatzi, Theodora Bampouri, Athina Chasapi, Ilianna Bei, Periklis Davlouros, George Hahalis and Dimitrios Alexopoulos.
DOI: 10.2174/1570161114666160625084427
Thursday, October 6, 2016
Friday, September 30, 2016
Editor’s Choice Article from the Journal Current Vascular Pharmacology
2:35 AM
No comments
Current Vascular Pharmacology, 13(4): 423-432
Clinical Zheng-hou Pharmacology: the Missing Link between Pharmacogenomics and Personalized Medicine?
Author(s): Ya-Nan Yu, Jun Liu, Lei Zhang, Zhong Wang, Dayue Darrel Duan and Yong-Yan Wang
Affiliation: Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, 18 Baixincang, Dongzhimennen, Beijing 100700, China.
Abstract: In Chinese medicine, Zheng-hou, instead of disease, is used to define complex medical problems in clinical practice. In the postgenomics era, it becomes particularly compelling to review the application of Zheng-houin characterizing complex clinical problems independent of disease or syndrome. While disease or syndrome describes a pathological phenotype or phenotypes, Zheng-hou spells the pathological phenome. Clinical Zheng-hou pharmacology (CZP) is an emerging clinical discipline that aims to leverage breakthroughs in the genome-wide solutions for complex medical problems through a combination of the current “omics” technology and the knowledge of Chinese medicine. The concept of CZP suggests that systematic and standard studies of multiple phenotypes will be important because of the collaborative cross between diversified external and internal factors at different levels both in vitro and in vivo. In this paper, we discuss the novel phenomic approaches to the understanding of Zheng-hou and the link of pharmacogenomics to personalized medicine through CZP, or pharmacophenomics. CZP enables ever-finer mapping of Zheng-hou and detection of dynamic variations in most current omics platforms. Although major challenges still remain in identifying and effectively investigating the diversity of Zheng-hou, CZP is expected to pave new paths to the systemic understanding of medical problems. While still at early stages in the clinical phenome domain, there remains great promise that CZP can help us realize the application of personalized medicine and contribute to rational holistic diagnosis and treatment.
courtesy by : Bentham Insight
Abstract: In Chinese medicine, Zheng-hou, instead of disease, is used to define complex medical problems in clinical practice. In the postgenomics era, it becomes particularly compelling to review the application of Zheng-houin characterizing complex clinical problems independent of disease or syndrome. While disease or syndrome describes a pathological phenotype or phenotypes, Zheng-hou spells the pathological phenome. Clinical Zheng-hou pharmacology (CZP) is an emerging clinical discipline that aims to leverage breakthroughs in the genome-wide solutions for complex medical problems through a combination of the current “omics” technology and the knowledge of Chinese medicine. The concept of CZP suggests that systematic and standard studies of multiple phenotypes will be important because of the collaborative cross between diversified external and internal factors at different levels both in vitro and in vivo. In this paper, we discuss the novel phenomic approaches to the understanding of Zheng-hou and the link of pharmacogenomics to personalized medicine through CZP, or pharmacophenomics. CZP enables ever-finer mapping of Zheng-hou and detection of dynamic variations in most current omics platforms. Although major challenges still remain in identifying and effectively investigating the diversity of Zheng-hou, CZP is expected to pave new paths to the systemic understanding of medical problems. While still at early stages in the clinical phenome domain, there remains great promise that CZP can help us realize the application of personalized medicine and contribute to rational holistic diagnosis and treatment.
courtesy by : Bentham Insight